Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. Haase D, et al. Among authors: haferlach t, haferlach c. Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11. Leukemia. 2019. PMID: 30635634 Free PMC article.
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
Schoch C, Haase D, Fonatsch C, Haferlach T, Löffler H, Schlegelberger B, Hossfeld DK, Becher R, Sauerland MC, Heinecke A, Wörmann B, Büchner T, Hiddemann W. Schoch C, et al. Among authors: haferlach t. Br J Haematol. 1997 Dec;99(3):605-11. doi: 10.1046/j.1365-2141.1997.4473257.x. Br J Haematol. 1997. PMID: 9401073 Free article.
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: haferlach t. Leukemia. 2000 Feb;14(2):226-31. doi: 10.1038/sj.leu.2401668. Leukemia. 2000. PMID: 10673737
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
Braess J, Jahns-Streubel G, Schoch C, Haase D, Haferlach T, Fiegl M, Voss S, Kern W, Schleyer E, Hiddemann W. Braess J, et al. Among authors: haferlach t. Br J Haematol. 2001 Jun;113(4):975-82. doi: 10.1046/j.1365-2141.2001.02866.x. Br J Haematol. 2001. PMID: 11442492 Free article.
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M, Kern W, Löffler H, Hiddemann W. Schoch C, et al. Among authors: haferlach t. Genes Chromosomes Cancer. 2002 Sep;35(1):20-9. doi: 10.1002/gcc.10088. Genes Chromosomes Cancer. 2002. PMID: 12203786
[Diagnostics and therapy of acute myeloid leukemia].
Kern W, Haferlach T, Schoch C, Hiddemann W. Kern W, et al. Among authors: haferlach t. Dtsch Med Wochenschr. 2002 Oct 18;127(42):2208-13. doi: 10.1055/s-2002-34943. Dtsch Med Wochenschr. 2002. PMID: 12397550 German. No abstract available.
704 results